Canadian Lung Radiotherapy Trial Directory
Below is a list of multi-center lung radiation trials currently running, or pending activation, in Canada.
To obtain a protocol or open a trial at your centre, please use the contact information below.
To obtain a protocol or open a trial at your centre, please use the contact information below.
Stage I NSCLC
LUSTRE
|
|
Study Question:
Is there an improvement in local control rates for patients with early stage non-small cell lung cancer treated with stereotactic body radiotherapy compared to conventional radiotherapy? Principal Investigators: Dr. Anand Swaminath (Ontario Clinical Oncology Group) Dr. Tim Whelan (Ontario Clinical Oncology Group) Arm 1: Conventional radiotherapy Arm 2: Stereotactic body radiotherapy Target Accrual: 324 patients (108 patients in Arm 1, 216 patients in Arm 2) Status: Open to accrual ClinicalTrials.gov Identifier: NCT01968941 Contacts: Kathryn Cline ([email protected]) Sharon Nason ([email protected]) |
Stage III NSCLC
ALMERA
|
|
Study Question:
Does the addition of concurrent metformin to standard radiotherapy plus concurrent chemotherapy lead to improvement in cancer patient outcomes for patients with locally advanced non-small cell lung cancer? Principal Investigator: Dr. Theodoros Tsakiridis (Juravinski Cancer Centre) Arm 1: Standard radiotherapy (60-63 Gy for 6 weeks) + concurrent cisplatin based chemotherapy Arm 2: Standard radiotherapy (60-63 Gy for 6 weeks) + concurrent cisplatin based chemotherapy + metformin orally for 12 months Target Accrual: 94 patients (47 patients in each arm) Status: Open to accrual ClinicalTrials.gov Identifier: NCT02115464 Contacts: Dr. Theodoros Tsakiridis ([email protected]) Kathryn Cline ([email protected]) |
OLIGOMETASTATIC NSCLC
SABR-COMET
|
|
Study Question:
Can stereotactic ablative radiotherapy lead to improvements in overall survival and quality of life in selected patients with oligometastatic disease compared to current approaches of chemotherapy and conventional radiotherapy? Principal Investigator: Dr. David Palma (London Health Sciences Centre) Arm 1: Palliative radiotherapy and/or Chemotherapy at discretion of treating medical oncologist Arm 2: SABR; Chemotherapy at discretion of treating medical oncologist Target Accrual: 99 patients (66 patients in Arm 1, 33 patients in Arm 2) Status: Accrual completed, results maturing ClinicalTrials.gov Identifier: NCT01446744 Click here to read the published protocol |